Humanetics gains $3.8 million grant to further develop radiation drug
Minneapolis-based Humanetics Corp., specializing in radiation resistance, has been awarded $3.8 million in grant funding from the U.S. Department of Defense (DOD) to advance BIO 300, a revolutionary drug aimed at protecting individuals from radiation exposure, a Business Wire article said. Read More »